The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

New gene patent suit sparks talk of trolls

A month after a unanimous U.S. Supreme Court struck down seven Myriad Genetics patents tied to two breast cancer susceptibility genes, the company has touched off another legal knock-down-drag-out to enforce other intellectual property unaffected by the decision—with consequences likely to include a new wave of patent-assertion litigation across the industry.

Earlier this month, Myriad sued two rivals in U.S. District Court, Utah District, claiming they infringed 10 patents associated with BRCA1 and BRCA2 that were not covered by the Supreme Court’s June 13 ruling.

Does Myriad’s latest lawsuit indeed mean that patent trolling has come to biopharma?

Read the full article here: New Gene Patent Suit Sparks Talk of Trolls

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend